Injectable BPC-157 Using BPC-157 as a subcutaneous injection is our preferred route for tendon, ligament, muscle, and post-surgical healing
They are not a current standard of care
The mean age at diagnosis was 10.6 months (range: 2 to 45 months)
Determining when someone is appropriate for microdosing begins with understanding their why. Through one-on-one consultations, our providers explore what each patient hopes to achieve, whether thats cardiovascular support, inflammation management, metabolic optimization, or longevity promotion
Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer
Role of neuroinflammation in neurodegeneration: new insights